Clinical Safety and Performance of GATT-Patch in Open Liver Surgery

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-16

Study Completion Date

2022-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the clinical safety and performance of GATT-Patch for management of haemorrhage during elective open liver surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of the Use of the New Hemostatic Patch Hemopatch ® in Patients Undergoing Surgical Liver Resection

NCT02769754

Liver Damage Surgery

UNKNOWN PHASE3

Thrombin Generation in Liver Transplant Surgery

NCT04762550

Liver Transplantation Thrombin Hemostasis, Surgical +2 more

UNKNOWN

Periinterventional Coagulation Management of Patients Undergoing a TIPS

NCT04421924

Liver Cirrhosis

RECRUITING NA

ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery - Liver Bleeding is Encountered

NCT02264730

Bleeding

UNKNOWN PHASE1

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

NCT01563458

Acquired Bleeding Disorder Bleeding During/Following Surgery

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The GATT-Patch study is a prospective, single arm, multicenter, pre-market, first-in-man clinical investigation, that intents to determine the clinical safety and performance of GATT-Patch for management of haemorrhage during elective open liver surgery.

The clinical investigation will be carried out in a maximum of 7 sites in The Netherlands, treating an estimated total of 51 participants. All participants will be thoroughly screened and if found eligible, treated with GATT-Patch during open liver surgery. Participants will be followed for 6 weeks with an additional ultrasound assessment at the 6 week follow up visit.

The participant enrolment period is expected to take approximately 6 months, with a total expected duration of the clinical investigation of approximately 8 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhage, Surgical

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GATT-Patch

GATT-Patch will be used to control bleeding during open liver surgery. Each surgery will be performed according to the standard procedures at the hospital, with the exception of the use of GATT-Patch.

Group Type EXPERIMENTAL

GATT-Patch

Intervention Type DEVICE

Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GATT-Patch

Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is scheduled to undergo an elective open surgery on the liver;
* Participant is willing and able to give written informed consent for investigation participation;
* Participant is 18 years of age or older at the time of enrollment;
* Participant has been informed of the nature of the clinical investigation.

* Participant in whom the Investigator is able to identify a target bleeding site at the liver resection plane for which any applicable conventional means for hemostasis (e.g. suture, ligature or cautery) are ineffective or impractical and the choice is made to use a topical hemostat for control of hemostasis; and the choice is made to use a topical hemostat for control of hemostasis;
* Participant has a minimal, mild, or moderate target bleeding;

Exclusion Criteria

* Participant is scheduled to undergo surgery on other organs besides the liver (e.g. pancreas, colon, lungs);
* Participant is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, allowing exclusive use of acetylsalicylic acid;
* Participant has platelet count \<100 x 10ˆ9/L, an activates partial thrombin time of \>100s, or international normalized ratio \>2.5;
* Participant is pregnant, planning on becoming pregnant or actively breast-feeding during the follow-up period;
* Participant has a known hypersensitivity to brilliant blue (FD\&C Blue #1);
* Participant has an active or suspected infection at the surgical site;
* Participant has a total bilirubin level of ≥ 2.5 mg/dl
* Participant has had or has planned to receive any organ transplantation;
* Participant has American Association of Anesthesiologists (ASA) classification of 4/5;
* Participant has a life expectancy of less than 3 months;
* Participant has a documented severe congenital or acquired immunodeficiency;
* Participant in whom the investigational device will be used at the site of a synthetic graft or patch implant;
* Participant is currently participating or has participated in another clinical investigation within the past 30 days that may affect the endpoints of the study, such as trials related to the surgical procedure, and on anti-coagulation;
* Participant is not appropriate for inclusion in the clinical investigation, per the medical opinion of the Investigator;
* Participant has any incidental (pre- and peri-operative) findings deemed by the Investigator to potentially jeopardize the safety or welfare of the patient

Eligible Sex

ALL

Accepts Healthy Volunteers

No